Switch to: References

Add citations

You must login to add citations.
  1. Ashley Revisited: A Response to the Critics.Douglas S. Diekema & Norman Fost - 2010 - American Journal of Bioethics 10 (1):30-44.
    The case of Ashley X involved a young girl with profound and permanent developmental disability who underwent growth attenuation using high-dose estrogen, a hysterectomy, and surgical removal of her breast buds. Many individuals and groups have been critical of the decisions made by Ashley's parents, physicians, and the hospital ethics committee that supported the decision. While some of the opposition has been grounded in distorted facts and misunderstandings, others have raised important concerns. The purpose of this paper is to provide (...)
    Download  
     
    Export citation  
     
    Bookmark   22 citations  
  • Medicalising short children with growth hormone? Ethical considerations of the underlying sociocultural aspects.Maria Cristina Murano - 2018 - Medicine, Health Care and Philosophy 21 (2):243-253.
    In 2003, the Food and Drug Administration approved the use of growth hormone treatment for idiopathic short stature children, i.e. children shorter than average due to an unknown medical cause. Given the absence of any pathological conditions, this decision has been contested as a case of medicalisation. The aim of this paper is to broaden the debate over the reasons for and against the treatment, to include considerations of the sociocultural phenomenon of the medicalisation of short stature, by means of (...)
    Download  
     
    Export citation  
     
    Bookmark   3 citations  
  • On the ethics of oestrogen treatment for tall girls: an update.P. Louhiala - 2009 - Journal of Medical Ethics 35 (11):713-714.
    New empirical evidence on the long-term effects of oestrogen treatment for tall adolescent girls has shown that the intended psychosocial benefit of the treatment may not have been realised. This paper describes recent trends in the prevalence of the treatment and the results of a large Australian cohort study evaluating girls assessed between 1959 and 1993 for excessive growth. The paper concludes that oestrogen treatment to prevent extreme tallness should belong to the past, not to the future.
    Download  
     
    Export citation  
     
    Bookmark  
  • The Ashley treatment: Best Interests, Convenience, and Parental Decision Making.S. Matthew Liao, Julian Savulescu & Mark Sheehan - 2007 - Hastings Center Report 37 (2):16-20.
    The story of Ashley, a nine-year-old from Seattle, has caused a good deal of controversy since it appeared in the Los Angeles Times on January 3, 2007.1 Ashley was born with a condition called static encephalopathy, a severe brain impairment that leaves her unable to walk, talk, eat, sit up, or roll over. According to her doctors, Ashley has reached, and will remain at, the developmental level of a three-month-old.
    Download  
     
    Export citation  
     
    Bookmark   10 citations